Stevanato Group S.p.A. (STVN)
USD 22.47
(-5.07%)
USD 22.47
(-5.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 341.67 Million EUR | -0.12% |
| 2022 | 319.8 Million EUR | 20.5% |
| 2021 | 265.4 Million EUR | 36.68% |
| 2020 | 194.17 Million EUR | 40.69% |
| 2019 | 138.02 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 59.35 Million EUR | -37.63% |
| 2024 Q2 | 64.69 Million EUR | 6.79% |
| 2023 Q1 | 76.25 Million EUR | -23.89% |
| 2023 FY | 319.43 Million EUR | -0.12% |
| 2023 Q4 | 95.16 Million EUR | 14.79% |
| 2023 Q3 | 82.9 Million EUR | 5.07% |
| 2023 Q2 | 78.9 Million EUR | 3.46% |
| 2022 Q2 | 74.57 Million EUR | 10.56% |
| 2022 Q1 | 67.44 Million EUR | -7.6% |
| 2022 FY | 319.8 Million EUR | 20.5% |
| 2022 Q4 | 100.2 Million EUR | 29.23% |
| 2022 Q3 | 77.53 Million EUR | 3.98% |
| 2021 Q1 | 65.4 Million EUR | 11.62% |
| 2021 FY | 265.4 Million EUR | 36.68% |
| 2021 Q4 | 73 Million EUR | 15.37% |
| 2021 Q3 | 63.27 Million EUR | -0.65% |
| 2021 Q2 | 63.69 Million EUR | -2.63% |
| 2020 Q4 | 58.6 Million EUR | 24.1% |
| 2020 FY | 194.17 Million EUR | 40.69% |
| 2020 Q3 | 47.22 Million EUR | -3.33% |
| 2020 Q2 | 48.85 Million EUR | 23.66% |
| 2020 Q1 | 39.5 Million EUR | 0.0% |
| 2019 FY | 138.02 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alcon Inc. | 5.6 Billion USD | 93.907% |
| AptarGroup, Inc. | 1.26 Billion USD | 72.956% |
| Baxter International Inc. | 4.97 Billion USD | 93.132% |
| Becton, Dickinson and Company | 9.15 Billion USD | 96.267% |
| Bausch + Lomb Corporation | 2.5 Billion USD | 86.355% |
| Haemonetics Corporation | 676.53 Million USD | 49.496% |
| Envista Holdings Corp | 1.45 Billion USD | 76.444% |
| ResMed Inc. | 2.6 Billion USD | 86.903% |
| Teleflex Incorporated | 1.64 Billion USD | 79.254% |
| Warby Parker Inc. | 365.22 Million USD | 6.447% |
| West Pharmaceutical Services, Inc. | 1.12 Billion USD | 69.742% |